<DOC>
	<DOCNO>NCT02976753</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness Elocta compare conventional factor product prophylactic treatment patient haemophilia A 24-month prospective period . Data also collect 12 month retrospective period .</brief_summary>
	<brief_title>Prospective , Non-interventional Study Evaluate Effectiveness Elocta Compared Conventional Factor Products</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patient diagnosis haemophilia A Received prophylactic treatment factor product management haemophilia A 12 month prior enrolment At enrolment prescribe prophylactic treatment Elocta conventional factor product regardless participation study Having least 12 month document prestudy treatment data regard prophylactic treatment prescription bleed episode prior baseline visit Signed date informed consent provide patient patient 's legally acceptable representative patient legal age studyrelated activity undertaken . Assent obtain paediatric patient accord local regulation Enrolment concurrent clinical interventional study involve intake investigational medicinal product ( IMP ) , within 1 year prior enrolment Previously treat commercially available extend halflife product Elocta Presence factor VIII inhibitor ( â‰¥0.60 Bethesda Unit [ BU ] /mL ) late available inhibitor test use Nijmegen modify Bethesda assay</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Blood Coagulation Disorders</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Coagulation Protein Disorders</keyword>
	<keyword>Hemorrhagic Disorders</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
</DOC>